Search

Chinese

In Vitro Services

Drug-Drug Interaction

In Vitro Services
Services & Solutions / Drug Metabolism & Pharmacokinetics (DMPK) / In Vitro Services / Drug-Drug Interaction
IN THIS SECTION
Drug Discovery
Chemistry
Custom Synthesis Medicinal Chemistry Process Chemistry Services & Manufacturing
Biology
ADME • Tox Screening
Metabolic Stability CYP Interaction Permeability & Transporters Physicochemical Properties Protein Binding Metabolite Identification Discovery PK & Toxicology
Pharmacology
Drug Development
Drug Metabolism & Pharmacokinetics (DMPK)
In Vitro Services In Vivo Services
Safety Assessment & Toxicology
Safety Pharmacology Genetic Toxicology Toxicology Global Pathology Services Toxicokinetics Standard for Exchange of Nonclinical Data (SEND)
Clinical Services
About the Clinic Clinical Study Experience Biometrics
Laboratory Testing Services
Bioanalytical – Small & Large Molecules
Method Development & Validation Modalities Technology Platforms Services Assays List Finder
Genomics
Oncology Pharmacogenetics Metagenomics & Microbiome
Central Lab Services
Histology & Pathology Safety Testing & Specialty Lab Testing Biorepository Services Clinical Trial Logistics Services Clinical Sample Processing Biospecimen Data Services Central Lab e-Portal Sample Management Central Lab Clinical Trial Request Intake Form
Biomarkers & Precision Medicine
CMC-Product Development & Manufacturing
Product Development
Formulation Development Clinical Trial Material (CTM) Manufacturing Commercial Manufacturing
Analytical Services
Analytical Small Molecule Microbiological Services
Biologics Cell & Gene Therapy
Biologics Services Cell & Gene Therapy Services GMP Routine Testing Services Stability Program
Agrochemical

The evaluation of the potential of candidate drugs to undergo drug-drug interactions is an important undertaking in drug development.

Our team of scientists evaluate the potential of the drug candidate to act as a perpetrator (determination of the IC50 or Ki of inhibition of CYP or other enzymes of interest) and victim (reaction phenotyping) of drug-drug interactions. 

  • CYP Inhibition 
  • CYP Induction 
  • CYP Reaction Phenotyping 
  • Reaction Phenotyping of non-CYP enzymes (UGT, SULT, FMO, aldehyde oxidase, MAO, etc.) 
  • Inhibition of non-CYP enzymes (UGT, SULT, FMO, aldehyde oxidase, MAO, etc.) 

Data obtained from these studies will be included in product label to ensure the safe use of drugs

Kinetics of Inactivation of CYP2C19 by ABC

Replicate #kinact(min-1) KI(μM) kinact/KI (mL/min/µmol) 
1 0.04742 6.584 7.20 
2 0.04813 5.466 8.81 
3 0.04679 6.128 7.64 
Mean ± SD 0.04745±0.00067 6.059±0.562 7.88±0.83 

Discover the following In Vitro services at Frontage

Resources To Consider

Left arrow
Drug-drug Interaction Study of CYP3A4 Inhibitors with Colchicine Oral Solution
journal

Drug-drug Interaction Study of CYP3A4 Inhibitors with Colchicine Oral…
The primary objective of the study was to compare the pharmacokinetic (PK) variables of pl…
Access Resource
Drug-drug Interaction Study of Carvedilol with Colchicine Oral Solution
poster

Drug-drug Interaction Study of Carvedilol with Colchicine Oral…
In this abstract, we discuss a Phase 1, open-label, two-period, sequential study to assess…
Access Resource
Right arrow